Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition
- 15 April 2021
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 137 (15), 2057-2069
- https://doi.org/10.1182/blood.2020008017
Abstract
Cancer and normal cells utilize multiple anti-apoptotic BCL2 proteins to prevent cell death. Therapeutic targeting of multiple BCL2 family proteins enhances tumor killing, but is also associated with increased systemic toxicity. Here, we demonstrate that the dual targeting of MCL1 and BCL2 proteins, using the small molecules S63845 and venetoclax, induces durable remissions in mice harboring human DLBCL tumors but is accompanied by hematological toxicity and weight loss. To mitigate these toxicities, we encapsulated S63845 or venetoclax into nanoparticles targeting P-selectin that is enriched in tumor endothelial cells. In vivo and ex vivo imaging demonstrated preferential targeting of the nanoparticles to lymphoma tumors over vital organs. Mass-spectrometry analyses after nanoparticle drug administration confirmed tumor enrichment of the drug while reducing plasma levels. Furthermore, nanoparticle encapsulation allowed 3.5 to 6.5-fold reduction in drug dose, induced sustained remissions and minimized toxicity. Our results support the development of nanoparticles to deliver BH3 mimetic combinations in lymphoma and in general for toxic drugs in cancer therapy.Keywords
This publication has 43 references indexed in Scilit:
- A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In VivoMolecular Cancer Therapeutics, 2014
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7Nature, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Mcl-1 Is Essential for Germinal Center Formation and B Cell MemoryScience, 2010
- Drugs targeting Bcl-2 family members as an emerging strategy in cancerExpert Reviews in Molecular Medicine, 2010
- Single-Step Assembly of Homogenous Lipid−Polymeric and Lipid−Quantum Dot Nanoparticles Enabled by Microfluidic Rapid MixingACS Nano, 2010
- Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human plateletsBiochimica et Biophysica Acta (BBA) - General Subjects, 2008
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem CellsScience, 2005
- Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1Nature, 2003